PANG.MC Pangaea Oncology S.A.
- Market cap
- EUR 52.8M
- P/E
- -
- P/B
- 2.48x
- ROE
- -16.9%
- Dividend yield
- -
- Fundamental score
- 1.4/5
Ratios use the latest price and the fiscal year ending Dec 2025.
Is PANG.MC undervalued?
Graham numberThe Graham number of Pangaea Oncology S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pangaea Oncology S.A. fundamental analysis
6 of 21 checks passedROE 0/2
Low return on equity (-16.9%), below 10%.
ROA 0/1
Return on assets (-11.2%) is below the industry median (-1.9%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-174.8%) is below the industry median (41.0%).
Revenue Growth 2/2
Revenue grew 49.3% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (27.3%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.0 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (2.5x) is above the industry median (2.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Pangaea Oncology S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pangaea Oncology S.A.
Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling and transcriptomic signatures; and tumor mutational burden (TMB) and microsatelli…
Full company profilePangaea Oncology S.A. financial statements
Pangaea Oncology S.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.52M | 2.62M | 3.06M | 3.32M | 4.10M | 4.60M | 4.37M | 8.00M | 14.3M | 14.5M |
| Gross Profit | 4.41M | 3.47M | 4.29M | 4.41M | 4.61M | 5.17M | 4.11M | 7.75M | 14.3M | 14.4M |
| Operating Income | -543K | -2.71M | -1.78M | -4.79M | -1.66M | -533K | 2.56M | -2.74M | 2.06M | -3.64M |
| EBITDA | -232K | -904K | 740K | -1.71M | 730K | 147K | -1.41M | -1.56M | 1.19M | -946K |
| Net Income | -595K | -1.65M | -1.25M | -4.84M | -1.79M | -642K | -2.71M | -4.66M | -1.17M | -3.60M |
| EPS | -0.06 | -0.15 | -0.09 | -0.28 | -0.09 | -0.03 | -0.09 | -0.15 | -0.04 | -0.11 |
| Balance Sheet | ||||||||||
| Total Assets | 17.9M | 19.0M | 20.4M | 16.9M | 17.2M | 20.8M | 28.4M | 28.8M | 32.4M | 32.1M |
| Total Liabilities | 11.9M | 13.9M | 11.7M | 8.56M | 8.61M | 6.76M | 5.30M | 10.0M | 9.57M | 10.0M |
| Shareholders' Equity | 6.05M | 5.05M | 8.62M | 8.31M | 8.57M | 14.1M | 23.1M | 17.8M | 22.1M | 21.3M |
| Cash & Short-term Investments | 4.20M | 1.32M | 1.42M | 1.17M | 300K | 2.93M | 8.51M | 2.79M | 4.43M | 3.07M |
| Total Debt | 3.56M | 12.2M | 4.76M | 3.72M | 6.75M | 5.36M | 3.49M | 5.73M | 5.61M | 5.82M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.78M | -6.48M | -2.17M | -2.40M | -1.92M | -2.50M | -3.68M | -2.40M | -4.57M | -2.52M |
| Capital Expenditure | 548K | 154K | 27.3K | 984.00 | 71.0K | 29.7K | 20.1K | 291K | 520K | 472K |
| Free Cash Flow | -2.33M | -6.63M | -2.19M | -2.40M | -1.99M | -2.53M | -3.70M | -2.69M | -5.08M | -2.99M |
| Ratios | ||||||||||
| ROE | -9.8% | -32.6% | -14.5% | -58.2% | -20.9% | -4.6% | -11.8% | -26.1% | -5.3% | -16.9% |
| ROA | -3.3% | -8.7% | -6.2% | -28.7% | -10.4% | -3.1% | -9.6% | -16.1% | -3.6% | -11.2% |
| Net Profit Margin | -23.6% | -62.8% | -41.0% | -146.0% | -43.8% | -13.9% | -62.1% | -58.2% | -8.2% | -24.8% |
| Debt to Equity | 0.59x | 2.42x | 0.55x | 0.45x | 0.79x | 0.38x | 0.15x | 0.32x | 0.25x | 0.27x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pangaea Oncology S.A. dividends
Pangaea Oncology S.A. has not paid dividends in the last 10 fiscal years.
Who owns Pangaea Oncology S.A.
- Insiders 69.26%
- Institutions 0.34%
- Public & others 30.41%
- Shares outstanding 35.9M
- Free float 30.9M
Pangaea Oncology S.A. company profile
- Company name
- Pangaea Oncology S.A.
- Ticker
- PANG.MC
- ISIN
- ES0105221008
- Exchange
- Madrid Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 165
- Fiscal year end
- December
- Address
- Calle Coso nº 55, 3º, Zaragoza, Spain
- Phone
- 34 93 409 79 81
- Website
- panoncology.com
About Pangaea Oncology S.A.
Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling and transcriptomic signatures; and tumor mutational burden (TMB) and microsatellite instability and (MSI) assessment services. It also provides diagnostic platforms validation and pre-clinical services. Pangaea Oncology, S.A. was incorporated in 2006 and is based in Zaragoza, Spain.
Pangaea Oncology S.A. management
7- Mr. Javier Rivela-Rodriguez C.F.A., M.B.A.Co-Founder, CEO & Director
- Dr. Rafael Rosell Costa M.D., Ph.D.Chief Scientific Officer, Director, President & Member of Scientific Committee
- Alejandro Garcia Moncayo M.B.A.Executive Director of Corporate & CFO
- Ms. Carmen AlbiolHead of Operations for IOR
- Dr. Miguel Angel Molina B.Sc., Ph.D.Executive Director of Research & Development and Member of Scientific Committee
- Alejandro Martinez M.D.Chief Medical Officer & Medical Director at IOR (Hospital Universitari Dexeus)
- Cristina Masferrer EMBAChief Business Officer